Nytricx Management

Dr. Shebuski is highly experienced pharmacologist with a broad drug development background in large pharma and cardiovascular biotech start-ups. Before directing the Cardiovascular Therapeutics group at Pharmacia & Upjohn, Dr. Shebuski was a Senior Scientist responsible for leading cardiovascular drug discovery teams at Merck and Smith Kline & French Laboratories.

Dr. Handa is an Associate Professor in the College of Engineering at the University of Georgia-Athens with over ten years industrial and academic experience in nitric oxide (NO)-releasing materials, surface science, coating development, antibacterial and hemocompatible materials and small animal models. Nytricx novel technology is based on work from his laboratory (37 NO-related publications) on development of NO-releasing surfaces that function as anti-thrombotic and anti-microbial platforms.

Dr. Brisbois is an Assistant Professor in the College of Engineering at the UGA-Athens, with over ten years of background and technical experience in analytical/materials chemistry. Dr. Brisbois has expertise in biomedical engineering, specifically in the field of nitric oxide (NO)-releasing biomaterials for biocompatible medical device applications, and has numerous publications, patents and research funding from NIH, JDRF, and CDC.

Mr. Delehanty has worked in various discovery research laboratories and in several administrative and financial positions at the Upjohn Company, Pharmacia & Upjohn and Pfizer before co-founding PharmOptima, LLC, a Contract Research Company in 2003.

Nytricx Management

Ronald Shebuski

Hitesh Handa

Elizabeth Brisbois

Patrick Delehanty

About